$RXMD Key Financial Highlights for Year Ended December 31, 2021 • Revenue at $38.9 million - COVID-19 testing revenue of approximately $4.3 million - ClearMetrX TPA and pharmacy dispensing revenue related to 340B earned $2.8 million on total billings of $19 million • Gross margin increased to 26% in 2021, from 23% in 2020 • EBITDA increased to $167,000 in 2021 from $7,000 in 2020 • Cash balance of $1.4 million as of December 31, 2021 https://www.otcmarkets.com/stock/RXMD/news/Progressive-Care-Reports-Full-Year-2021-Financial-Results-Highlighted-by-389-Million-in-Revenue?id=349785